<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202472">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453791</url>
  </required_header>
  <id_info>
    <org_study_id>SF2105450</org_study_id>
    <nct_id>NCT00453791</nct_id>
  </id_info>
  <brief_title>The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics</brief_title>
  <official_title>A Randomised, Single and Repeat Dose, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be the First Time in Human Study (FTIH) aiming to assess the safety and
      tolerability of GW805858 for both single and repeat dose. The study also aims to assess
      safety and tolerability in mild asthmatic subjects as well as healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability parameters will be compared between active and placebo treatment groups using summary statistics. No formal statistical analyses of the safety and tolerability data will be performed.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Derived GW805858 and GW288967 PK parameters will be compared between active and placebo treatment groups using summary statistics.</measure>
  </secondary_outcome>
  <enrollment>54</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW805858</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of non-child bearing potential, aged between 18 and 60 years of age
             inclusive.

          -  Body weight = 50 kg (110 lbs) for men and = 45 kg for women and Body Mass Index (BMI)
             within the range 19.0-30.0 kg/m2 inclusive.

          -  The subject is a current non-smoker who has not used any tobacco products in the last
             year.

          -  A signed and dated written informed consent is obtained for the subject.

          -  The subject is able to understand and comply with protocol requirements and
             timetables, instructions and protocol-stated restrictions.

          -  If asthmatic, the subject must be a clinically stable asthmatic.

        Exclusion Criteria:

          -  The subject has a history of allergy to ingredients within the inhaler.

          -  The subject has received an investigational drug or participated in any other
             research trial within 30 days, prior to the first dose of current study medication.

          -  The subject has used prescription or non-prescription drugs, including vitamins,
             herbal and dietary supplements (including St John's Wort) within 14 days prior to the
             first dose of study medication.

          -  The subject has an average weekly alcohol intake of greater than 21 units if male or
             14 units if female.

          -  The subject has any history of breathing problems (e.g. history of asthmatic
             symptoms).

          -  The subject is infected with the hepatitis B, hepatitis C, or HIV virus.

          -  The subject has had a respiratory tract infection or worsening of asthma within 4
             weeks of the start of the study.

          -  The subject has a past or present disease, which as judged by the Investigator, may
             affect the outcome of this study.

          -  The subject has a history of life-threatening asthma, defined as an asthma episode
             that required intubation and/or was associated with hypercapnea, respiratory arrest
             or hypoxia seizures.

          -  The subject has taken inhaled, nasal or dermal steroids within 4 weeks or oral
             steroids within 8 weeks of the start of the study.

          -  The subject is unable to abstain from other drugs that may interfere with the conduct
             of the study.

          -  The subject has ongoing rhinitis that requires treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW20 0NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>May 31, 2012</lastchanged_date>
  <firstreceived_date>March 27, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW805858</keyword>
  <keyword>MDI</keyword>
  <keyword>asthma</keyword>
  <keyword>surfactant</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
